Surgical Considerations in Patients Receiving Neoadjuvant Systemic Therapy

• Rastogi P , AndersonSJ, BearHDet al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J. Clin. Oncol. 26(5), 778–785 (2008).
   PubMed Web of Science ®Google Scholar
• Mauri D , PavlidisN, IoannidisJP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.J. Natl Cancer Inst.97(3), 188–194 (2005).
   PubMedGoogle Scholar
• Mieog JS , van der HageJA, van de VeldeCJ. Neoadjuvant chemotherapy for operable breast cancer.Br. J. Surg.94(10), 1189–1200 (2007).
   PubMed Web of Science ®Google Scholar
• Caudle AS , Gonzalez-AnguloAM, HuntKKet al. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 28(11), 1821–1828 (2010).
   PubMed Web of Science ®Google Scholar
• Fisher B , BryantJ, WolmarkNet al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J. Clin. Oncol. 16(8), 2672–2685 (1998).
   PubMed Web of Science ®Google Scholar
• Bonadonna G , ValagussaP, BrambillaCet al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J. Clin. Oncol. 16(1), 93–100 (1998).
   PubMed Web of Science ®Google Scholar
• Kuerer HM , NewmanLA, SmithTLet al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J. Clin. Oncol. 17(2), 460–469 (1999).
   PubMed Web of Science ®Google Scholar
• Kong X , MoranMS, ZhangN, HafftyB, YangQ. Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients.Eur. J. Cancer47(14), 2084–2090 (2011).
   PubMed Web of Science ®Google Scholar
• Jeruss JS , MittendorfEA, TuckerSLet al. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J. Clin. Oncol. 26(2), 246–252 (2008).
   PubMed Web of Science ®Google Scholar
• Mittendorf EA , JerussJS, TuckerSLet al. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. J. Clin. Oncol. 29(15), 1956–1962 (2010).
   Google Scholar
• Mauriac L , MacGroganG, AvrilAet al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann. Oncol. 10(1), 47–52 (1999).
   PubMed Web of Science ®Google Scholar
• Fisher B , BrownA, MamounasEet al. Effect of preoperative chemotherapy on local–regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J. Clin. Oncol. 15(7), 2483–2493 (1997).
   PubMed Web of Science ®Google Scholar
• Wolmark N , WangJ, MamounasE, BryantJ, FisherB. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18.J. Natl Cancer Inst. Monogr.2001(30), 96–102 (2001).
   Google Scholar
• Cochrane RA , ValasiadouP, WilsonAR, Al-GhazalSK, MacmillanRD. Cosmesis and satisfaction after breast-conserving surgery correlates with the percentage of breast volume excised.Br. J. Surg.90(12), 1505–1509 (2003).
   PubMed Web of Science ®Google Scholar
• Buchholz TA , LehmanCD, HarrisJRet al. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference. J. Clin. Oncol. 26(5), 791–797 (2008).
   PubMed Web of Science ®Google Scholar
• van der Hage JA , van de VeldeCJ, JulienJPet al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10.02. J. Clin. Oncol. 19(22), 4224–4237 (2001).
   PubMed Web of Science ®Google Scholar
• Rouzier R , MathieuMC, SiderisLet al. Breast-conserving surgery after neoadjuvant anthracycline-based chemotherapy for large breast tumors. Cancer 101(5), 918–925 (2004).
   PubMed Web of Science ®Google Scholar
• Guarneri V , BroglioK, KauSWet al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J. Clin. Oncol. 24(7), 1037–1044 (2006).
   PubMed Web of Science ®Google Scholar
• Cristofanilli M , Gonzalez-AnguloA, SneigeNet al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J. Clin. Oncol. 23(1), 41–48 (2005).
   PubMed Web of Science ®Google Scholar
• Boughey JC , PeintingerF, Meric-BernstamFet al. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann. Surg. 244(3), 464–470 (2006).
   PubMed Web of Science ®Google Scholar
• Chen AM , Meric-BernstamF, HuntKKet al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson Cancer Center experience. J. Clin. Oncol. 22(12), 2303–2312 (2004).
   PubMed Web of Science ®Google Scholar
• Cabioglu N , HuntKK, SahinAAet al. Role for intraoperative margin assessment in patients undergoing breast-conserving surgery. Ann. Surg. Oncol. 14(4), 1458–1471 (2007).
   PubMed Web of Science ®Google Scholar
• Chen AM , Meric-BernstamF, HuntKKet al. Breast conservation after neoadjuvant chemotherapy. Cancer 103(4), 689–695 (2005).
   PubMed Web of Science ®Google Scholar
• Huang EH , StromEA, PerkinsGHet al. Comparison of risk of local–regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score. Int. J. Radiat. Oncol. Biol. Phys. 66(2), 352–357 (2006).
   PubMed Web of Science ®Google Scholar
• Akay CL , Meric-BernstamF, HuntKKet al. Evaluation of the MD Anderson prognostic index for local–regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy. Ann. Surg. Oncol. doi: 10.1245/s10434-011-2006-7 (2011) (Epub ahead of print).
   Google Scholar
• Mittendorf EA , BuchholzTA, TuckerSLet al. Impact of chemotherapy timing on local–regional failures in patients with breast cancer undergoing breast-conserving therapy. Presented at: American Society of Clinical Oncology Breast Cancer Symposium. San Francisco, CA, USA, 8–10 September 2011 (Abstract 82).
   Google Scholar
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472), 1687–1717 (2005).
   PubMed Web of Science ®Google Scholar
• Ellis MJ . Preoperative endocrine therapy for older women with breast cancer: renewed interest in an old idea.Cancer Control7(6), 557–562 (2000).
   PubMedGoogle Scholar
• Ota DM , NelsonH, EllisM, HuntK. Measuring the impact of Z1031 on clinical practice.Bull. Am. Coll. Surg.96(5), 57–59(2011).
   Google Scholar
• Ellis MJ , SumanVJ, HoogJet al. Randomized Phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype – ACOSOG Z1031. J. Clin. Oncol. 29(17), 2342–2349 (2011).
   PubMed Web of Science ®Google Scholar
• Smith IE , DowsettM, EbbsSRet al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J. Clin. Oncol. 23(22), 5108–5116 (2005).
   PubMed Web of Science ®Google Scholar
• Eiermann W , PaepkeS, AppfelstaedtJet al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann. Oncol. 12(11), 1527–1532 (2001).
   PubMed Web of Science ®Google Scholar
• Kuerer HM , SahinAA, HuntKKet al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann. Surg. 230(1), 72–78 (1999).
   PubMed Web of Science ®Google Scholar
• Bear HD , AndersonS, BrownAet al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J. Clin. Oncol. 21(22), 4165–4174 (2003).
   PubMed Web of Science ®Google Scholar
• van Deurzen CH , VriensBE, Tjan-HeijnenVCet al. Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: a systematic review. Eur. J. Cancer 45(18), 3124–3130 (2009).
   PubMed Web of Science ®Google Scholar
• Xing Y , FoyM, CoxDDet al. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br. J. Surg. 93(5), 539–546 (2006).
   PubMed Web of Science ®Google Scholar
• Nason KS , AndersonBO, ByrdDRet al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer 89(11), 2187–2194 (2000).
   PubMed Web of Science ®Google Scholar
• Mamounas EP , BrownA, AndersonSet al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J. Clin. Oncol. 23(12), 2694–2702 (2005).
   PubMed Web of Science ®Google Scholar
• Krag DN , AndersonSJ, JulianTBet al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised Phase III trial. Lancet Oncol. 8(10), 881–888 (2007).
   PubMed Web of Science ®Google Scholar
• Kim T , GiulianoAE, LymanGH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis.Cancer106(1), 4–16 (2006).
   PubMed Web of Science ®Google Scholar
• Hunt KK , YiM, MittendorfEAet al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann. Surg. 250(4), 558–566 (2009).
   PubMed Web of Science ®Google Scholar
• Krishnamurthy S , SneigeN, BediDGet al. Role of ultrasound-guided fine-needle aspiration of indeterminate and suspicious axillary lymph nodes in the initial staging of breast carcinoma. Cancer 95(5), 982–988 (2002).
   PubMed Web of Science ®Google Scholar
• Hennessy BT , HortobagyiGN, RouzierRet al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J. Clin. Oncol. 23(36), 9304–9311 (2005).
   PubMed Web of Science ®Google Scholar
• Dominici LS , Negron GonzalezVM, BuzdarAUet al. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer 116(12), 2884–2889 (2010).
   PubMed Web of Science ®Google Scholar
• Shen J , GilcreaseMZ, BabieraGVet al. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Cancer 109(7), 1255–1263 (2007).
   PubMed Web of Science ®Google Scholar
• Gimbergues P , AbrialC, DurandoXet al. Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation. Ann. Surg. Oncol. 15(5), 1316–1321 (2008).
   PubMed Web of Science ®Google Scholar
• Classe JM , BordesV, CampionLet al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J. Clin. Oncol. 27(5), 726–732 (2009).
   PubMed Web of Science ®Google Scholar
• Hatzis C , PusztaiL, ValeroVet al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 305(18), 1873–1881 (2011).
   PubMed Web of Science ®Google Scholar

Website

• ClinicalTrials.gov. http://clinicaltrials.gov (Accessed 30 October 2011)
   Google Scholar